- Home
- NTLA vs CRF Comparison
NTLA vs CRF Comparison
Compare NTLA & CRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- CRF
- Stock Information
- Founded
- NTLA 2014
- CRF 1973
- Country
- NTLA United States
- CRF United States
- Employees
- NTLA N/A
- CRF N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CRF Finance/Investors Services
- Sector
- NTLA Health Care
- CRF Finance
- Exchange
- NTLA Nasdaq
- CRF Nasdaq
- Market Cap
- NTLA 1.2B
- CRF 1.2B
- IPO Year
- NTLA 2016
- CRF N/A
- Fundamental
- Price
- NTLA $12.27
- CRF $8.03
- Analyst Decision
- NTLA Buy
- CRF
- Analyst Count
- NTLA 20
- CRF 0
- Target Price
- NTLA $25.83
- CRF N/A
- AVG Volume (30 Days)
- NTLA 9.7M
- CRF 1.1M
- Earning Date
- NTLA 11-06-2025
- CRF 01-01-0001
- Dividend Yield
- NTLA N/A
- CRF 18.10%
- EPS Growth
- NTLA N/A
- CRF N/A
- EPS
- NTLA N/A
- CRF 1.40
- Revenue
- NTLA $52,857,000.00
- CRF $11,461,786.00
- Revenue This Year
- NTLA $9.20
- CRF N/A
- Revenue Next Year
- NTLA N/A
- CRF N/A
- P/E Ratio
- NTLA N/A
- CRF $5.38
- Revenue Growth
- NTLA 14.99
- CRF 6.53
- 52 Week Low
- NTLA $5.90
- CRF $5.70
- 52 Week High
- NTLA $28.25
- CRF $9.56
- Technical
- Relative Strength Index (RSI)
- NTLA 32.04
- CRF 53.88
- Support Level
- NTLA $13.21
- CRF $7.86
- Resistance Level
- NTLA $26.35
- CRF $8.09
- Average True Range (ATR)
- NTLA 1.91
- CRF 0.09
- MACD
- NTLA -1.94
- CRF -0.00
- Stochastic Oscillator
- NTLA 3.07
- CRF 57.81
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.